Αθηροσκλήρωσησ

Η ΠΟΔΟΚΥΤΤΟΥΡΙΑ ΣΤΗ ΔΙΑΒΗΤΙΚΗ ΝΕΦΡΟΠΑΘΕΙΑ 51Βιβλιογραφία1. Zelmanovitz T, Gerchman F, Balthazar AP et al. Diabetic nephropathy.Diabetol Metab Syndr 2009, 1:102. Stitt-Cavanagh E, MacLeod L, Kennedy CRJ. The podocyte in diabetickidney disease. Scient World J 2009, 9:1127–11393. Standards of medical care in diabetes, 2009. Diabet Care 2009,32(Suppl 1):13–614. Remuzzi G, Benigni A, Remuzzi A. Mechanisms of progressionand regression of renal lesions of chronic nephropathies and diabetes.J Clin Invest 2006, 116:288–2965. Parving HH, Lehnert H, Brochner-Mortensen J et al. The effect ofirbesartan on the development of diabetic nephropathy in patientswith type 2 diabetes. N Engl J Med 2001, 345:870–8786. Mogensen CE, Christensen CK. Predicting diabetic nephropathy ininsulin-dependent patients. N Engl J Med 1984, 311:89–937. Basi S, Lewis JB. Microalbuminuria as a target to improve cardiovascularand renal outcomes in diabetic patients. Curr Diab Rep 2007,7:439–4428. Klausen KP, Scharling H, Jensen JS. Very low level of microalbuminuriais associated with increased risk of death in subjects with cardiovascularor cerebrovascular diseases. J Intern Med 2006, 260:231–2379. Mathieson PW. Update on the podocyte. Curr Opin Nephrol Hypertens2009 18:206–21110. Michaud JL, Kennedy CR. The podocyte in health and disease:insights from the mouse. Clin Sci (Lond) 2007, 112:325–33511. Tervaert TW, Mooyaart AL, Amann K et al. Pathologic classificationof diabetic nephropathy. J Am Soc Nephrol 2010, 21:556–56312. Comper WD, Russo LM. Where does albuminuria come from in diabetickidney disease? Curr Diab Rep 2008, 8:477–48513. Lewis EJ, Xu X. Abnormal glomerular permeability characteristicsin diabetic nephropathy: implications for the therapeutic use of lowmolecularweight heparin. Diabet Care 2008, 31(Suppl 2): 202–20714. Satchell SC, Tooke JE. What is the mechanism of microalbuminuriain diabetes: a role for the glomerular endothelium? Diabetologia 2008,51:714–72515. Shankland SJ. The podocyte’s response to injury: role in proteinuriaand glomerulosclerosis. Kidney Int 2006, 69:2131–214716. Meyer TW, Bennett PH, Nelson RG. Podocyte number predicts longtermurinary albumin excretion in Pima Indians with Type II diabetesand microalbuminuria. Diabetologia 1999, 42:1341–134417. Jefferson JA, Shankland SJ, Pichler RH. Proteinuria in diabetic kidneydisease: a mechanistic viewpoint. Kidney Int 2008, 74: 22–3618. Chen HC, Chen CA, Guh JY et al. Altering expression of alpha3beta1integrin on podocytes of human and rats with diabetes. Life Sci 2000,67:2345–235319. Susztak K, Raff AC, Schiffer M et al. Glucose-induced reactive oxygenspecies cause apoptosis of podocytes and podocyte depletion at theonset of diabetic nephropathy. Diabetes 2006, 55:225–23320. Liu Y. Renal fibrosis: new insights into the pathogenesis and therapeutics.Kidney Int 2006, 69:213–21721. Coward RJ, Welsh GI, Koziell A et al. Nephrin is critical for the actionof insulin on human glomerular podocytes. Diabetes 2007, 56:1127–113522. Welsh GI, Hale LJ, Eremina V et al. Insulin signaling to the glomerularpodocyte is critical for normal kidney function. Cell Metab 2010,12:329–34023. Welsh GI, Saleem MA. Nephrin-signature molecule of the glome rularpodocyte? J Pathol 2010, 220:328–33724. Lee SH, Yoo TH, Nam BY et al. Activation of local aldosterone systemwithin podocytes is involved in apoptosis under diabetic conditions.Am J Physiol Renal Physiol 2009, 297:1381–139025. Steffes MW, Schmidt D, McCrery R et al. Glomerular cell numberin normal subjects and in type 1 diabetic patients. Kidney Int 2001,59:2104–201326. Pagtalunan ME, Miller PL, Jumping-Eagle S et al. Podocyte loss andprogressive glomerular injury in type II diabetes. J Clin Invest 1997,99:342–34827. Dalla Vestra M, Masiero A, Roiter AM et al. Is podocyte injury relevantin diabetic nephropathy? Studies in patients with type 2 diabetes.Diabetes 2003, 52:1031–103528. White KE, Bilous RW. Structural alterations to the podocyte are relatedto proteinuria in type 2 diabetic patients. Nephrol Dial Transplant2004, 19:1437–144029. Habara P, Mareckova H, Sopkova Z et al. A novel method for the estimationof podocyte injury: podocalyxin-positive elements in urine.Folia Biol (Praha) 2008, 54:162–16730. Hara M, Yanagihara T, Itoh M et al. Immunohistochemical and urinarymarkers of podocyte injury. Pediatr Nephrol 1998, 12:43–4831. Hara M, Yanagihara T, Kihara I. Urinary podocytes in primary focalsegmental glomerulosclerosis. Nephron 2001, 89:342–34732. Nakamura T, Ushiyama C, Suzuki S et al. Urinary podocytes for theassessment of disease activity in lupus nephritis. Am J Med Sci 2000,320:112–11633. Petermann AT, Krofft R, Blonski M et al. Podocytes that detach inexperimental membranous nephropathy are viable. Kidney Int 2003,64:1222–123134. Petermann AT, Pippin J, Krofft R et al. Viable podocytes detach inexperimental diabetic nephropathy: potential mechanism underlyingglomerulosclerosis. Nephron Exp Nephrol 2004, 98: 114–12335. Nakamura T, Ushiyama C, Suzuki S et al. Urinary excretion of podocytesin patients with diabetic nephropathy. Nephrol Dial Transplant2000, 15:1379–138336. Sharma S, Bonal D, Thomas D et al. Urinary excretion of podocytes asan early marker of diabetic nephropathy. National Kidney Foundation2010, Spring Clinical Meetings Abstracts, 201037. Nakamura T, Kawagoe Y, Koide H. Effect of cigarette smoking on urinarypodocyte excretion in early diabetic nephropathy. Diabet Care2003, 26:1324–132538. Nakamura T, Ushiyama C, Osada S et al. Pioglitazone reduces urinarypodocyte excretion in type 2 diabetes patients with microalbuminuria.Metabolism 2001, 50:1193–119639. Miglio G, Rosa AC, Rattazzi L et al. The subtypes of peroxisome proliferator-activatedreceptors expressed by human podocytes and theirrole in decreasing podocyte injury. Br J Pharmacol 201040. Nakamura T, Ushiyama C, Shimada N et al. Effect of the antiplateletdrug dilazep dihydrochloride on urinary podocytes in patients in theearly stage of diabetic nephropathy. Diabet Care 2000, 23:1168–117141. Nakamura T, Kawagoe Y, Ogawa H et al. Effect of low-density lipoproteinapheresis on urinary protein and podocyte excretion in patientswith nephrotic syndrome due to diabetic nephropathy. Am J KidneyDis 2005, 45:48–5342. Barutta F, Corbelli A, Mastrocola R et al. Cannabinoid receptor 1blockade ameliorates albuminuria in experimental diabetic nephropathy.Diabetes 2010, 59:1046–105443. Bonnet F, Cooper ME, Kawachi H et al. Irbesartan normalises thedeficiency in glomerular nephrin expression in a model of diabetesand hypertension. Diabetologia 2001, 44:874–87744. Cai Y, Chen Y, Zheng S et al. Sirolimus damages podocytes in rats withprotein overload nephropathy. J Nephrol 201045. Ruester C, Franke S, Bondeva T et al. Erythropoietin ProtectsPodocytes from Damage by Advanced Glycation End-Products.Nephron Exp Nephrol 2010, 117:e21–e3046. Sakoda M, Ichihara A, Kurauchi-Mito A et al. Aliskiren inhibits intracellularangiotensin II levels without affecting (pro)renin receptor signalsin human podocytes. Am J Hypertens 2010, 23:575–580Ημερομηνία Υποβολής 05/10/2010Ημερομηνία Έγκρισης 25/11/2010© 2011 Ελληνική Εταιρεία Αθηροσκλήρωσης